Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

27 citing papers in PubMed, 64 citations in OpenAlex.

1. Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment.Clinical pharmacokinetics · 2018
   Trial
2. OXR1 is a dual redox-mitochondrial checkpoint governing osteoclast differentiation and bone loss in an osteoporosis mouse model.Nature communications · 2026
   Article
3. In silico and in vitro investigations of novel Siglec-1 inhibitors in a microglial cell model.Naunyn-Schmiedeberg's archives of pharmacology · 2026
   Article
4. Potential Drug Interactions in Psychiatric Patients Undergoing Pangenotypic Therapy for Hepatitis C Virus Infection.Pharmaceuticals (Basel, Switzerland) · 2026
   Review
5. Trends in the seroprevalence of hepatitis C viruses among patients received at the Centre Pasteur du Cameroun, with an indication of anti-HCV Ac serology from 2019 to 2024.BMC infectious diseases · 2025
   Article
6. Real-life study on the effectiveness and safety of sofosbuvir/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patients.Journal of virus eradication · 2024
   Article
7. Asymmetric Synthesis of US-FDA Approved Drugs over Five Years (2016-2020): A Recapitulation of Chirality.Pharmaceuticals (Basel, Switzerland) · 2023
   Review
8. The Burden of Inappropriate Prescriptions and Predictors for Hospitalized Patients with Liver Cirrhosis in Ethiopia.Hepatic medicine : evidence and research · 2023
   Article
9. Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection.World journal of hepatology · 2022
   Review
10. Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections.World journal of gastroenterology · 2022
    Article
11. Progress, evolving therapeutic/diagnostic approaches, and challenges in the management of hepatitis C virus infections.Archives of virology · 2022
    Review
12. Sensitive Determination of SARS-COV-2 and the Anti-hepatitis C Virus Agent Velpatasvir Enabled by Novel Metal-Organic Frameworks.ACS omega · 2021
    Article
13. In silico identification of available drugs targeting cell surface BiP to disrupt SARS-CoV-2 binding and replication: Drug repurposing approach.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2021
    Article
14. SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19.Expert opinion on therapeutic patents · 2021
    Review
15. Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan.Hepatology international · 2021
    Article
16. The current state of validated small molecules inhibiting SARS-CoV-2 nonstructural proteins.Turkish journal of biology = Turk biyoloji dergisi · 2021
    Review
17. Development and Clinical Application of Phosphorus-Containing Drugs.Medicine in drug discovery · 2020
    Review
18. Accelerating the repurposing of FDA-approved drugs against coronavirus disease-19 (COVID-19).RSC advances · 2020
    Article
19. Cost-utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China.BMJ open · 2020
    Article
20. Real-world Effectiveness of Sofosbuvir/Velpatasvir for Treatment of Chronic Hepatitis C in British Columbia, Canada: A Population-Based Cohort Study.Open forum infectious diseases · 2020
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as